Table 2.

Key intracellular pathway and epigenetic targets and potential therapies

CategoryTargetPotential agents
BTK inhibitors BTK Ibrutinib 
 BTK Acalabrutinib 
 BTK ONO/GS-4059 
 BTK BGB-3111 
 BTK CC-292 
PI3K inhibitors PI3Kδ Idelalisib 
 PI3K δ and γ Duvelisib 
 PI3K δ and α Copanlisib 
 PI3Kδ TGR1202 
Syk inhibitors Syk Fostamatinib* 
 Syk Entospletinib 
BCL2 inhibitors BCL2 Venetoclax 
MDM2 inhibitors MDM2 Idasanutlin 
 MDM2 DS-3032b 
Epigenetic modifiers EZH2 Tazemetostat 
 EZH2 CPI-1205 
 EZH2 GSK2816126 
CategoryTargetPotential agents
BTK inhibitors BTK Ibrutinib 
 BTK Acalabrutinib 
 BTK ONO/GS-4059 
 BTK BGB-3111 
 BTK CC-292 
PI3K inhibitors PI3Kδ Idelalisib 
 PI3K δ and γ Duvelisib 
 PI3K δ and α Copanlisib 
 PI3Kδ TGR1202 
Syk inhibitors Syk Fostamatinib* 
 Syk Entospletinib 
BCL2 inhibitors BCL2 Venetoclax 
MDM2 inhibitors MDM2 Idasanutlin 
 MDM2 DS-3032b 
Epigenetic modifiers EZH2 Tazemetostat 
 EZH2 CPI-1205 
 EZH2 GSK2816126 
*

No longer in development in NHL.